CA3221668A1 — Daprodustat for reducing fatigue in a subject with anemia associated with chronic kidney disease
Assigned to GlaxoSmithKline Intellectual Property No 2 Ltd · Expires 2022-12-29 · 3y expired
What this patent protects
The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in non-dialysis subjects with anemia associated with chronic kidney disease. In particular embodiments, the invention is directed to particular subject populatio…
USPTO Abstract
The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in non-dialysis subjects with anemia associated with chronic kidney disease. In particular embodiments, the invention is directed to particular subject populations in which the subject has hsCRP ?6.60 mg/L at baseline and in which the subject has a haemoglobin 5 concentration of ?11 g/dL at baseline.
Drugs covered by this patent
- Jesduvroq (DAPRODUSTAT) · GSK
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.